Salesforce stock heads into Monday: Spring ’26 rollout and earnings clock put CRM back in focus

Salesforce stock heads into Monday: Spring ’26 rollout and earnings clock put CRM back in focus

New York, January 11, 2026, 14:38 EST — Market closed.

  • Salesforce shares dipped 0.23% on Friday, closing at $259.94.
  • Salesforce announced its Spring ’26 product update, featuring fresh AI, data, and automation capabilities, will begin rolling out on Feb. 23. (Salesforce)
  • Salesforce is set to release its earnings on Feb. 25, after the market closes, per Yahoo Finance’s earnings calendar. (Yahoo Finance)

Salesforce, Inc. shares slipped roughly 0.2% to close at $259.94 on Friday, following the company’s announcement of its Spring ’26 product release. The update, featuring a suite of new tools, is set to begin rolling out on Feb. 23. U.S. markets will resume trading Monday after the weekend hiatus.

This update is crucial as Salesforce pushes to convert its “AI agents” concept into revenue before the upcoming earnings release. These AI agents—software bots—handle routine tasks within business apps, cutting down on manual labor.

Investors are pressing a straightforward question: do the new tools drive renewals, expansions, and new deals, or are they just impressive demos? In the coming weeks, a product rollout and earnings report should provide at least part of the answer.

In early December, Salesforce boosted its fiscal 2026 revenue forecast to a range of $41.45 billion to $41.55 billion. The company reported that current remaining performance obligations, which track contracted revenue expected over the next 12 months, jumped 11% to $29.4 billion. Annual recurring revenue (ARR) for Agentforce and Data 360 hit nearly $1.4 billion. CEO Marc Benioff confirmed the company was “raising fiscal year 2026 revenue guidance,” while CFO Robin Washington said the strong adoption “reinforces our path” to reaching longer-term goals. (Salesforce Investor Relations)

Risk appetite remains solid. The S&P 500 and Dow closed Friday at new highs despite a mixed U.S. jobs report, with the Nasdaq posting gains as well. (AP News)

Salesforce announced that its Spring package brings an AI-powered sales workspace, service tools aimed at catching problems before they turn into support cases, and a two-way email feature allowing automated agents to handle routine replies. The company also spotlighted an “Agentforce Builder” interface designed to accelerate how firms create and test agents.

Enterprise software stocks diverged sharply on Friday. Oracle jumped 4.95%, but ServiceNow slipped 3%, highlighting a patchwork of individual company drivers instead of a unified sector move. (MarketWatch)

Salesforce shares have dropped 18.5% in the last 52 weeks, per Yahoo Finance, currently trading far below their 52-week peak of $367.09. (Yahoo Finance)

The Spring rollout kicks off in late February, and traders will be watching closely to see if customers are actively using the new tools rather than just dabbling. During the earnings call, the focus typically lands on subscription growth, backlog developments, operating margin, and any news on share buybacks.

Yet, new product launches don’t automatically translate into spending. If companies cut back on tech budgets or put off upgrades, the boost from these tools might come later—or might never materialize.

Next week packs in major U.S. lenders kicking off earnings season, alongside a slew of conferences and economic reports that could reshape rate forecasts. Software stocks will be sensitive to these moves, reacting not just to company updates but also to yield fluctuations. (Investors)

Salesforce has two key dates ahead: Feb. 23 marks the start of the Spring ’26 release rollout, while Feb. 25 is when Wall Street anticipates the company will report earnings and update its guidance.

Stock Market Today

  • Profound Medical: Top TSX Growth Stock Poised for Rapid Expansion, Q3 Revenues Surge 87%
    February 1, 2026, 9:22 PM EST. Profound Medical (TSX:PRN), a Canadian medical device firm specializing in MRI-guided ultrasound therapies, is highlighted as the sole TSX growth stock to hold for the next three years. The company reported an 87% revenue increase in Q3 to $5.3 million, driven by expanded installations of its flagship TULSA-PRO prostate cancer treatment system. Offering incision-free, MRI-guided ablation technology, Profound's procedures have gained Medicare approval with rising insurance reimbursements. Despite a net loss of $8 million, the company improved gross margins to 74.3% and ended Q3 with $25 million cash, supporting near-term liquidity. With 70 systems installed and 93 in advanced sales stages, Profound aims for 75 installations by year-end, making it a notable small-cap growth stock in healthcare on the TSX.
Lam Research stock (LRCX) jumps on Mizuho target hike — what to watch into Monday and the week ahead
Previous Story

Lam Research stock (LRCX) jumps on Mizuho target hike — what to watch into Monday and the week ahead

Nestle stock (NESN) in focus: Hong Kong recall update keeps traders on edge ahead of Monday
Next Story

Nestle stock (NESN) in focus: Hong Kong recall update keeps traders on edge ahead of Monday

Go toTop